Two of the largest drugmakers in the country are investing in a startup applying artificial intelligence in pathology. Boston-based PathAI said that it had closed its $75 million Series B financing round with funding from New York-based Bristol-Myers Squibb and the Merck Global Health Innovation Fund, part of Kenilworth, New Jersey-based Merck & Co. PathAI said it would use the money to bolster its clinical development capabilities. PathAI had announced its $60 million Series B financing its April, led by venture capital firms General Atlantic and General Catalyst, with participation from LabCorp, which the company said the latest investment follows and extends.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
Biosimilar
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
Diagnostics
Digital Health
Drug Discovery
EpiVax'
FDA
FDA approval
funding
fundraising
HIV
Immunogenicity
Immunotherapies
INVO Bioscience
Licensing
M&A
medical device
microbiome
Neuro
next-gen sequencing
NGS
PathAI
pathology
Pepticom
peptides
pharma
PierianDx
RNA
robots
Shape Therapeutics
skin
software
SurgiMab
Therapeutics
therapies
USA
VIrology
Virus